Company Arix Bioscience plc

Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company's core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company's subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.

Number of employees: 9